Literature DB >> 16636194

Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats.

Yayoi Ishikawa1, Toshio Nishikimi, Kazumi Akimoto, Kimihiko Ishimura, Hidehiko Ono, Hiroaki Matsuoka.   

Abstract

We have shown recently that fasudil, a Rho-kinase inhibitor, has renoprotective effects in salt-sensitive hypertensive rats. We hypothesized that activation of Rho-kinase is involved in the pathogenesis of glomerulosclerosis in malignant hypertensive rats. To test this hypothesis, we studied the following 4 groups: control Wistar-Kyoto rats, untreated deoxycorticosterone-acetate salt spontaneously hypertensive rats (DOCA-SHR), low-dose fasudil-treated DOCA-SHR, and high-dose fasudil-treated DOCA-SHR. After 3 weeks of treatment, the effects of fasudil were examined. DOCA-SHR was characterized by increased blood pressure (BP); increased kidney weight; decreased renal function; increased proteinuria; abnormal histological findings; increased monocyte/macrophage infiltration; increased urinary 8-isoprostran levels; increased gene expression of collagen I, collagen III, transforming growth factor-beta, and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits (p40phox, p47phox, and p67phox); and decreased gene expression of endothelial NO synthase (eNOS) in the renal cortex as compared with Wistar-Kyoto rats. Long-term high-dose fasudil treatment significantly improved renal function and histological findings without changing BP, as compared with untreated DOCA-SHR. Interestingly, long-term fasudil treatment significantly decreased monocyte/macrophage infiltration and urinary 8-isoprostran excretion, in association with decreased mRNA levels of transforming growth factor-beta, collagen I, collagen III, and NADPH oxidase subunits (p40phox, p47phox, and p67phox), and increased mRNA levels of eNOS in the renal cortex. Long-term low-dose fasudil treatment tended to improve these variables slightly but did not affect most of them significantly. Our results suggest that long-term fasudil treatment provides renoprotective effects independent of BP-lowering activity. These renoprotective effects are associated with inhibition of extracellular matrix gene expression, monocyte/macrophage infiltration, oxidative stress, and upregulation of eNOS gene expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636194     DOI: 10.1161/01.HYP.0000221605.94532.71

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

Review 1.  The role of Rho protein signaling in hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Nat Rev Cardiol       Date:  2010-08-31       Impact factor: 32.419

2.  End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899.

Authors:  Matthias Löhn; Oliver Plettenburg; Aimo Kannt; Markus Kohlmann; Armin Hofmeister; Dieter Kadereit; Peter Monecke; Alexander Schiffer; Anke Schulte; Hartmut Ruetten; Yuri Ivashchenko
Journal:  World J Cardiol       Date:  2015-01-26

Review 3.  Cell-matrix adhesion of podocytes in physiology and disease.

Authors:  Norman Sachs; Arnoud Sonnenberg
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

Review 4.  Rho kinase inhibition in diabetic kidney disease.

Authors:  Radko Komers
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

5.  Role of guanine nucleotide exchange factor-H1 in complement-mediated RhoA activation in glomerular epithelial cells.

Authors:  Flaviana Mouawad; Lamine Aoudjit; Ruihua Jiang; Katalin Szaszi; Tomoko Takano
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

6.  Tanshinone II a protects against lipopolysaccharides-induced endothelial cell injury via Rho/Rho kinase pathway.

Authors:  Wei Li; Wei Sun; Chuan-hua Yang; Hong-zhen Hu; Yue-hua Jiang
Journal:  Chin J Integr Med       Date:  2014-03-04       Impact factor: 1.978

Review 7.  Rho kinase proteins--pleiotropic modulators of cell survival and apoptosis.

Authors:  Catharine A Street; Brad A Bryan
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

Review 8.  Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease.

Authors:  Xuefei Tian; Shuta Ishibe
Journal:  Nephrol Dial Transplant       Date:  2016-03-10       Impact factor: 5.992

Review 9.  Podocyte-actin dynamics in health and disease.

Authors:  Luca Perico; Sara Conti; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

Review 10.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.